Cognitive impairment, including decreased attention and memory, remains one of the most disabling aspects of schizophrenia, ...

WINDSOR, England and VALBY, Denmark, March 13, 2025 /PRNewswire/ -- Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has ...

Cognitive impairment, including decreased attention and memory, remains one of the most disabling aspects of schizophrenia, affecting social life of patients. However, no effective treatment has yet ...

NEW ORLEANS -- Brexpiprazole (Rexulti) helped ease agitation in people with Alzheimer's dementia, according to a phase III study. Over the course of the 12-week trial, patients on either a 2-mg or ...

Review the side-effects of Brexpiprazole as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

FDA advisors voted in favor of brexpiprazole (Rexulti) for treating agitation associated with Alzheimer's dementia (AAD), despite increased mortality risk. By a vote of 9-1 on Friday, members of the ...

Credit: Getty Images. If approved, brexpiprazole would be the first medication indicated for AAD in the US. The Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee and ...

A regulatory decision on the combination therapy is expected on February 8, 2025. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for ...

Portrait of a woman taking a pill. Some patients with schizophrenia may experience residual symptoms when treated with antipsychotics, due in part to their side effects. This analysis aims to examine ...

In a randomized clinical trial, researchers determined whether brexpiprazole is an efficacious, safe, and well-tolerated treatment for agitation in patients with Alzheimer dementia. Brexpiprazole, 2 ...

For many people living with dementia and their caregivers, the worst symptom of the disease is not memory loss, but agitation. Whether it comes out as verbal insults or physical violence, agitation in ...

Lundbeck and Otuska’s brexpiprazole-sertraline cocktail has hit the mark in a post-traumatic stress disorder (PTSD) phase 2. The data give Lundbeck a boost at a time when its recently installed CEO is ...